Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828226 | 0.89 | FFAR1 (0.55) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL2824000 | 0.89 | FFAR1 (0.61) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL2827628 | 0.88 | FFAR1 (0.54) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL2826986 | 0.81 | HRH3 (0.61) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL2827010 | 0.80 | FFAR1 (0.52) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL13887164 | 0.79 | LTA4H (0.61) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL13065796 | 0.79 | LTA4H (0.61) | NPC1RAB9AFFAR1TP53SMN1; SMN2 | |
| SCHEMBL4119205 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2HRH3 | |
| SCHEMBL2827371 | 0.78 | FFAR4 (0.57) | FFAR1FFAR4 | |
| SCHEMBL2828343 | 0.77 | FFAR1 (0.55) | NPC1RAB9AFFAR1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731505-B1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-14 | — | — | EP | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | GPR119, FFAR1, GPR55 | NPC1 1092/4885RAB9A 3353/4885FFAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.